Our Research

Our Research

>> Research Departments
>> Find Clinical Trials
>> Our Publications
>> Our Research Collaborations

Contact Details

  Street address:
Level 11, KGV Building
Missenden Road
Postal address:
Post Office Box M30
Missenden Road NSW 2050

Phone: (02) 9515-6111
Fax: (02) 9515-9610

Online Feedback


Our Research

Professor Anthony Keech is a Professor of Medicine, Cardiology and Epidemiology and Consultant Cardiologist at the Royal Prince Alfred Hospital.  He is Deputy Director of the NHMRC Clinical Trials Centre at the University of Sydney and holds an NHMRC Senior Principal Research Fellowship. He has co-led a team of researchers at the Clinical Trials Centre over the past 24 years (assisting in it growing from 24 to currently 150 staff) and for the last 10 years has chaired the CTC’s research committee, which has overall responsibility for the research directions, strategies and standards of all its research activities. Over 65,000 patients have been recruited to 100 multicentre trials involving >800 clinical His specialist areas are large trials to inform treatment strategies for acute coronary syndromes, risk factor reduction in cardiovascular disease, and prevention of vascular disease including in diabetes. He also works in the areas of microvascular complications of diabetes and underlying molecular mechanisms. He is Chair and Principal Investigator of the FIELD diabetes study.

Prof. Keech’s research has had a profound impact on health practice and health outcomes, particularly in treatments of acute myocardial infarction, lipids and CVD, prevention of chronic heart disease, and diabetes and its vascular complications. He is recognised internationally for collaborative research into coronary risk factors, treatments for acute coronary syndromes, prediction of vascular disease and treatment and diabetes complication prevention. Findings have been widely adopted and led to amended guidelines, policy and subsidy decisions.

Professor Chris Semsarian is leading a team that is embarking on breakthrough and internationally leading research in a fantastic example of collaboration between the University of Sydney, Royal Prince Alfred Hospital and the Centenary Institute. The team has been awarded two National Health and Medical Research Council grants. With a national success rate of 17 per cent, gaining two grants is testament of the calibre of the team and importance of their work.

One of the grants will look at the link between genetically-based sudden cardiac death and epilepsy; the other continues work on the genetic basis in families with hypertrophic cardiomyopathy. The overarching goal with both research pieces is to discover new gene faults in cases of hypertrophic cardiomyopathy and sudden death in epilepsy.  Using the latest technology the team will look into all 23,000 genes, in the hope of making life changing discoveries for patients and families living with these conditions.
Hypertrophic Cardiomyopathy is the most common genetic heart disorder. In about 50 per cent of cases the gene abnormality is unknown, and tragically in some cases the first sign of disease is sudden death.

Through the research, the team aims to identify gene faults and translate this into strategies to identify risk, treat patients accordingly, and most importantly prevent sudden death.

Professor David Celermajer is the Scandrett Professor of Cardiology at The University of Sydney and Director of Echocardiography in the Cardiology Department at Royal Prince Alfred Hospital, as well as Staff Cardiologist at the Children's Hospital in Westmead. He has been Group Leader of the Clinical Research Group of the the Heart Research Institute since 1994, and in 2003 was appointed as Clinical Director of the Heart Research Institute. He sits on the National Heart Foundation of Australia's Cardiovascular Health Advisory Committee and is currently also a Board Member of the Menzies School of Health Research in the Northern Territory.

Professor Celermajer's research is in three major areas:
Congenital heart disease
Pulmonary vascular disease

Professor Anushka Patel is a Professor of Medicine, UNSW Sydney and a cardiologist at Royal Prince Alfred Hospital in Sydney, Australia. She undertook her medical training at the University of Queensland, with subsequent postgraduate research degrees from Harvard University and the University of Sydney.
Her personal research interests focus on developing innovative solutions for delivering affordable and effective cardiovascular care in the community and in acute care hospital settings.

Professor Patel currently leads research projects relating to these interests in Australia, China and India. She is supported by a Senior Research Fellowship from the Australian National Health and Medical Research Council (NHMRC).

Dr Kim Chan is a Staff Specialist in Cardiology and Cardiac Electrophysiology at Royal Prince Alfred Hospital and a Clinical Senior Lecturer at the University of Sydney Medical School. He has completed National Heart Foundation funded PhD studies on vascular disease at the University of Sydney, followed by a 2 year postdoctoral clinical and research fellowship in Cardiac Electrophysiology at Loyola University Medical Center, Chicago, USA, under the mentorship of Prof David Wilber.

Dr Chan's current research outputs and interests include:
1. Assessment of atrial function/fibrosis using cardiac DE-MRI in patients with atrial fibrillation
2. Sleep apnoea and atrial arrhythmias
3. Role of endothelial progenitor cell populations in vascular regeneration
4. Role of heme oxygenase-1 in response to ischaemia

Clinical Trials The following trials are currently active in the Cardiology Department:
  • Global SYMPLICITY Registry, where SYMPLICITY stands for proSpective registrY for syMPathetic renaL denervatIon in seleCted Indications Through 3 - 5 Years. PI: A/Prof Lynne Pressley
  • Cardiac REsynchronisation Therapy (CRT) And AV Node ablation trial in AF (CAAN-AF). PI: Dr. Raymond Sy
  • A Cluster Randomized Trial of Objective Risk Assessment versus standard care for Acute Coronary Syndromes (AGRIS). PI: A/Prof Mark Adams
  • The Integrated Text Messaging (ITM) study for chronic respiratory and cardiovascular disease
    Technological support for patients with chronic respiratory and cardiovascular disease via integrated text messaging. PI: Dr. Lissa Spencer
  • A multicenter, randomized, double-blind, placebo controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients (RELAX-AHF 2). PI: A/Prof Jo-Dee Lattimore
  • Prospective, multi-center, double-blind, randomized, placebo-controlled,parallel-group study assessing the efficacy and safety of macitentan in Fontan-palliated adult and adolescent subjects. (RUBATO). PI: Prof David Celermajer (Under ethics approval)



Professor Anthony Keech

  • NHMRC Senior Principal Research Fellowship with SEO 2012-2016

Dr Belinda Gray

  • Cardiac Society of Australia and New Zealand Travelling Fellowship, European Society of Cardiology, Barcelona
  • Heart Rhythm Society (HRS) Annual Scientific Sessions, Finalist Young Investigator Awards.
  • Cardiac Society of Australia and New Zealand, Travelling Fellowship, CSANZ ASM.
  • Cardiac Society of Australia and New Zealand Annual Scientific Sessions (CSANZ), Finalist Ralph Reader Prize.

Dr Kaivan Vaidya

  • Cardiac Society of Australia and New Zealand Annual Scientific Sessions (CSANZ), Finalist Ralph Reader Prize.

Research Staff

  • Associate Professor Mark Adams
  • Professor Anthony Keech
  • Professor Anushka Patel
  • Professor Chris Semsarian
  • Professor David Celermajer
  • A/Prof Jo-Dee Lattimore
  • Clinical Associate Professor Sanjay Patel
  • Dr Belinda Gray
  • Dr Kaivan Vaidya
  • Dr Kim Chan
  • Dr Lisa Simmons
  • Dr Rachael Cordina

Higher Degree Students:

Supervisor Clinical Associate Professor Sanjay Patel:

  • Ms Zoe Clayton - SP PhD Primary Supervisor: thesis submitted May 2017. Two publications, one manuscript in preparation, 5 presentations in international meetings.
  • Dr Jennifer Barraclough - SP PhD Primary Supervisor, 2015-present. One publication, one manuscript under review, 2 presentations in international meetings.
  • Mr Jack Hywood - SP PhD Primary Supervisor, 2014-present. One manuscript in preperation, one presentation (finalist Ralph Reader Young investigator award CSANZ 2016).

Publications and Presentations

Publication Details:

Professor Anthony Keech:

  1. Abed HS, Fulcher J, Kilborn MJ, Keech AC. Inappropriate sinus tachycardia: focus on ivabradine. Internal Medicine Journal. 2016; 46(8): 875-883
  2. Bursell S-E, Zang S, Keech AC, Jenkins A.  Telehealth Reimbursement in Australia.  Medical Journal of Australia. Internal Medicine Journal 2016; 46(8): 977-981.
  3. Chia N, Fulcher J, Keech A. Beta-blocker, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, nitrate-hydralazine, diuretics, aldosterone antagonist, ivabradine, devices and digoxin (BANDAID2): an evidence based mnemonic for the treatment of systolic heart failure. Internal Medicine Journal 2016; 46(6): 653-662.
  4. Cholesterol Treatment Trialists' (CTT) Collaboration (Herrington WG, Emberson J, Mihaylova B, Blackwell L, ...Keech A, Simes J, Collins R, Baigent C). Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol 2016; 4(10): 829-839
  5. Hague WE, Simes J, Kirby A, Keech AC, White HD, Hunt D, Nestel PJ, Colquhoun DM, Pater H, Stewart RA, Sullivan DR, Thompson PL, West M, Glasziou PP, Tonkin AM. Long-term effectiveness and safety of pravastatin in patients with coronary heart disease: 16 years of follow-up of the LIPID Study. Circulation 2016; 133(19): 1851-1860.
  6. Januszewski AS, Sutanto SS, McLennan S, O'Neal D.N, Keech AC, Twigg SM, Jenkins AJ.  Shorter telomeres in adults with Type 1 diabetes correlate with diabetes duration, but only weakly with vascular function and risk factors. Diabetes Research and Clinical Practice. Diabetes Research and Clinical Practice 2016; 117: 4-11.
  7. Jenkins A, Januszewski A, Scott E, Keech A. What the primary care health practitioner should know about fenofibrate for their diabetes patients. Diabetes & Primary Care Australia. 2016; 2:30-34
  8. Oei JL, Ghadge A, Coates E, Wright IM, Saugstad OD, Vento M, Buonocore G, Nagashima T, Suzuki K, Hosono S, Davis PG, Craven P, Askie L, Dawson J, Garg S, Keech A, Rabi Y, Smyth J, Sinha S, Stenson B, Lui K, Hunter CL, Tarnow Mordi W. Clinicians in 25 countries prefer to use lower levels of oxygen to resuscitate preterm infants at birth. Acta Paediatrica 2016; 105(9): 1061-1066
  9. Reith C, Blackwell L, Emberson J,  ... Keech A, Simes J, Baigent C, Collins R. Protocol for analyses of adverse event data from randomized controlled trials of statin therapy. 10. Amer Heart J. 2016; 176: 63-69
  10. Sabatine MS, Giugliano RP, Keech A, Honarpour N, Wang H, Liu T, Wasserman SM, Scott R, Sever PS, Pedersen TR. Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. American Heart Journal 2016; 173: 94-101.
  11. Sherrah AG, Andvik S, van der Linde D, Davies L, Bannon PG, Padang R, Vallely MP, Wilson MK, Keech AC, Jeremy RW. Nonsyndromic thoracic aortic aneurysm and dissection: outcomes with Marfan syndrome versus bicuspid aortic valve aneurysm. Journal of the American College of Cardiology 2016; 67(6): 618-626
  12. Stern K, Cho YH, Benitez-Aguirre P, Jenkins AJ, McGill M, Mitchell P, Keech AC, Donaghue KC. QT interval, corrected for heart rate, is associated with HbA concentration and autonomic function in diabetes. Diabetic Medicine. 2016; 33 (10): 1415-1421
  13. Tarnow-Mordi W, Stenson B, Kirby A, Juszczak E, Donoghoe M, Deshpande S, Morley C, King A, Doyle L, Fleck BW, Davis P, Halliday HL, Hague W, Cairns P, Darlow BA, Fielder AR, Gebski V, Marlow N, Simmer K, Tin W, Ghadge A, Williams C, Keech A, Wardle SP, Kecskes Z, Kluckow M, Gole G, Evans N, Malcolm G, Luig M, Wright I, Stack J, Tan K, Pritchard M, Gray PH, Morris S, Headley B, Dargaville P, Simes RJ, Brocklehurst P. Outcomes of two trials of oxygen-saturation targets in preterm infants. New England Journal of Medicine 2016; 374(8): 749-760.
  14. Traill CL, Januszewski A, Larkins R, Keech AC, Jenkins AJ. Time to research Australian physician researchers. Internal Medicine Journal 2016; 46 (5) 550-558
  15. Traill CL, Januszewski A, Larkins R, Keech AC, Jenkins AJ. Time to research Australian female physician-researchers. Internal Medicine Journal 2016;. 46 (4): 412-419
  16. Williams  KH, Sullivan DR, Veillard, AS O'Brien, R, George J, Jenkins AJ, Young S,Ehnholm C. Duffield, A, Twigg SM, Keech AC. Low alanine aminotransferase levels and higher number of cardiovascular events in people with Type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetic Medicine 2016;  33 (3): 356-364 
  17. Williams KH, Sullivan DR, Nicholson GC, George J, Jenkins AJ, Januszewski AS, Gebski VJ, Manning P, Tan YM, Donoghoe MW, Ehnholm C, Young S, O'Brien R, Buizen L, Twigg SM, Keech AC. Opposite associations between alanine aminotransferase and gamma;-glutamyl transferase levels and all-cause mortality in type 2 diabetes: analysis of the fenofibrate intervention and event lowering in diabetes (FIELD) study. Metabolism: Clinical and Experimental 2016; 65(5): 783-793

Professor Anushka Patel

  1. Webster R, Patel A*, Selak V, Billot L, Bots ML, Brown A, Bullen C, Cass A, Crengle S, Elley CR, Grobbee DE, Neal B, Peiris D, Poulter N, Prabhakaran D, Rafter N, Stanton A, Stepien S, Thom S, Usherwood T,  Wadham A, Rodgers A, on behalf of the SPACE Collaboration. Effectiveness of fixed dose combination medication ('polypills') compared with usual care in patients with cardiovascular disease or at high risk: An individual patient data meta-analysis of 3140 patients in six countries. International Journal of Cardiology. 2016; 205: 147-156. (PMID: 26736090) [IF 4.638, Citations 24].
  2. Woodward M, Hirakawa Y, Kengne AP, Matthews DR, Zoungas S, Patel A, Poulter N, Grobbee D, Cooper M, Jardine M, Chalmers J. Prediction of ten year vascular risk amongst patients with diabetes: the AD-ON risk score. Diabetes, Obesity and Metabolism. 2016 Mar;18(3):289-94. (PMID: 26661693) [IF 6.198, Citations 3].
  3. Selak V, Bullen C, Stepien S, Arroll B, Bots M, Bramley D, Cass A, Grobbee DR, Hillis GS, Molanus B, Neal B, Patel A, Rafter N, Rodgers A, Thom S, Tonkin A, Usherwood T, Wadham A, Webster R. Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular disease. European Journal of Preventive Cardiology. 2016; 23(13):1393-1400. (IF 3.361, PMID: 26945024) [IF 2.638, Citations 2].
  4. Laba T, Patel A, Jan S. Creating a new investment pool for innovative health systems research. Australian Health Review 2016 Published online: 14 October, 2016 (IF0.820, PMID: 27736634)
  5. Peiris D, Sun L, Patel A, Tian M, Essue B, Jan S, Zhang P. Systematic Medical Assessment, Referral and Treatment for Diabetes care in China using Lay Family Health Promoters: Protocol for the SMART Diabetes cluster randomised controlled trial. Implementation Science 2016 Aug 17;11(1):116. (IF 3.201, PMID: 27535128) [IF 3.201, Citations 3].
  6. Hayek A, Joshi R, Usherwood T, Webster R, Kaur B, Saini B, Armour C, Krass I, Laba T-L, Reid C, Shiel L, Hespe C, Hersh F, Jan S, Lo Serigne, Peiris D, Rodgers A, Patel A*. An integrated general practice and pharmacy-based intervention to promote use of appropriate preventive medications among individuals at high cardiovascular disease risk: protocol for a cluster randomized trial. Implementation Science 2016 Sep 23;11(1):129. (PMID: 27664074) [IF 3.201, Citations 1].
  7. Li M, Huang Y, Du X, Li Shenshen, Ji J, Patel A, Gao R, Wu Y. Impact of Prior Use of Four Preventive Medications on Outcomes in Patients Hospitalized for Acute Coronary Syndrome--Results from CPACS-2 Study. PLoS ONE 2016; 11(9): e0163068. doi:10.1371/journal.pone.0163068. (PMID: 27626640) [IF 3.234, Citations 2].
  8. Mohammedi K, Woodward M, Zoungas S, Li Q, Harrap S, Patel A, Marre M, Chalmers J, on behalf of the ADVANCE Collaborative Group. Absence of peripheral pulses and risk of major vascular outcomes in patients with type 2 diabetes. Diabetes Care 2016; 39(12):2270-2277 (PMID: 27679583). [IF 8.934, Citations 1].
  9. Maulik PK, Tewari A, Devarapalli S, Kallakuri S, Patel A*. The Systematic Medical Appraisal, Referral and Treatment (SMART) Mental Health Project: Development and testing of an electronic decision support system and formative research to understand perceptions about mental health in rural India. PLoS One 2016 Oct 12;11(10):e0164404. doi: 10.1371/journal.pone.0164404. eCollection 2016 (PMID: 27732652) [IF 3.234, Citations 2].

Professor Chris Semsarian

  1. Burns C, Ingles J, Davis AM, Connell V, Gray B, Hunt L, McGaughran J and Semsarian C. Clinical and genetic features of Australian families with long QT syndrome: A registry-based study. J Arrhythm. 2016;32:456-461.
  2. Semsarian C and Ingles J. Molecular autopsy in victims of inherited arrhythmias. J Arrhythm. 2016;32:359-365.
  3. Sweeting J and Semsarian C. Sudden Cardiac Death in Athletes: Still Much to Learn. Cardiol Clin. 2016;34:531-541.
  4. Semsarian C and Bagnall RD. Sudden Cardiac Death in Children and Young Adults. N Engl J Med. 2016;375:1301-2.
  5. Ho CY, Cirino AL, Lakdawala NK, Groarke J, Valente AM, Semsarian C, Colan SD and Orav EJ. Evolution of hypertrophic cardiomyopathy in sarcomere mutation carriers. Heart. 2016.
  6. Sweeting J, Ingles J, Timperio A, Patterson J, Ball K and Semsarian C. Physical activity in hypertrophic cardiomyopathy: prevalence of inactivity and perceived barriers. Open Heart. 2016;3:e000484.
  7. Bagnall RD, Weintraub RG, Ingles J, Duflou J, Yeates L, Lam L, Davis AM, Thompson T, Connell V, Wallace J, Naylor C, Crawford J, Love DR, Hallam L, White J, Lawrence C, Lynch M, Morgan N, James P, du Sart D, Puranik R, Langlois N, Vohra J, Winship I, Atherton J, McGaughran J, Skinner JR and Semsarian C. A Prospective Study of Sudden Cardiac Death among Children and Young Adults. N Engl J Med. 2016;374:2441-52.
  8. Ross SB, Fraser ST and Semsarian C. Induced pluripotent stem cells in the inherited cardiomyopathies: From disease mechanisms to novel therapies. Trends Cardiovasc Med. 2016;26:663-672.
  9. Caleshu C, Kasparian NA, Edwards KS, Yeates L, Semsarian C, Perez M, Ashley E, Turner CJ, Knowles JW and Ingles J. Interdisciplinary psychosocial care for families with inherited cardiovascular diseases. Trends Cardiovasc Med. 2016;26:647-53.
  10. Gray B, Bagnall RD, Lam L, Ingles J, Turner C, Haan E, Davis A, Yang PC, Clancy CE, Sy RW and Semsarian C. A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2016;13:1652-60.
  11. Semsarian C and Ingles J. Preventing sudden cardiac death in athletes. BMJ. 2016;353:i1270.
  12. Viola H, Johnstone V, Cserne Szappanos H, Richman T, Tsoutsman T, Filipovska A, Semsarian C and Hool L. The L-type Ca(2+) channel facilitates abnormal metabolic activity in the cTnI-G203S mouse model of hypertrophic cardiomyopathy. J Physiol. 2016;594:4051-70.
  13. Ingles J, Spinks C, Yeates L, McGeechan K, Kasparian N and Semsarian C. Posttraumatic Stress and Prolonged Grief After the Sudden Cardiac Death of a Young Relative. JAMA Intern Med. 2016;176:402-5.
  14. Goldman AM, Behr ER, Semsarian C, Bagnall RD, Sisodiya S and Cooper PN. Sudden unexpected death in epilepsy genetics: Molecular diagnostics and prevention. Epilepsia. 2016;57 Suppl 1:17-25.
  15. Bagnall RD, Crompton DE, Petrovski S, Lam L, Cutmore C, Garry SI, Sadleir LG, Dibbens LM, Cairns A, Kivity S, Afawi Z, Regan BM, Duflou J, Berkovic SF, Scheffer IE and Semsarian C. Exome-based analysis of cardiac arrhythmia, respiratory control, and epilepsy genes in sudden unexpected death in epilepsy. Ann Neurol. 2016;79:522-34.
  16. Sweeting J, Ingles J, Ball K and Semsarian C. Sudden deaths during the largest community running event in Australia: A 25-year review. Int J Cardiol. 2016;203:1029-31.
  17. Burns C, McGaughran J, Davis A, Semsarian C and Ingles J. Factors influencing uptake of familial long QT syndrome genetic testing. Am J Med Genet A. 2016;170A:418-25.
  18. Lim WW, Baumert M, Neo M, Kuklik P, Ganesan AN, Lau DH, Tsoutsman T, Semsarian C, Sanders P and Saint DA. Slowed atrial and atrioventricular conduction and depressed HRV in a murine model of hypertrophic cardiomyopathy. Clin Exp Pharmacol Physiol. 2016;43:95-101.

Professor David Celermajer

  1. Cai TY, Magnussen C, Haluska B, Johnson DW, Mottram PM, Isbel N, Celermajer DS, Marwick TH, Skilton MR. Carotid extra-medial thickness does not predict adverse cardiovascular outcomes in high-risk adults. Diabetes Metab. 2016.
  2. Cai TY, Sullivan TR, Ayer JG, Harmer JA, Leeder SR, Toelle BG, Marks GB, Celermajer DS, Skilton MR. Carotid extramedial thickness is associated with local arterial stiffness in children. J Hypertens. 2016;34(1):109-15.
  3. Chia EM, Lau EM, Xuan W, Celermajer DS, Thomas L. Exercise testing can unmask right ventricular dysfunction in systemic sclerosis patients with normal resting pulmonary artery pressure. Int J Cardiol. 2016;204:179-86.
  4. Kizirian NV, Kong Y, Muirhead R, Brodie S, Garnett SP, Petocz P, Sim KA, Celermajer DS, Louie JC, Markovic TP, Ross GP, Ward LC, Brand-Miller JC, Skilton MR. Effects of a low-glycemic index diet during pregnancy on offspring growth, body composition, and vascular health: a pilot randomized controlled trial. Am J Clin Nutr. 2016;103(4):1073-82.
  5. Krishnan A, Drak D, Bao S, Celermajer DS, Liu J. A model of early transient pressure overload simulating repair of aortic coarctation in childhood. J Thorac Cardiovasc Surg.
  6. Kutty S, Rathod RH, Danford DFA, Celermajer DS. Role of imaging in the evaluation of single ventricle with the Fontan palliation. Heart. 2016;102(3):174-83.
  7. Lau EM, Chemla D, Godinas L, Zhu K, Sitbon O, Savale L, Montani D, Jais X, Celermajer DS, Simonneau G, Humbert M, Herve P. Loss of Vascular Distensibility During Exercise Is an Early Hemodynamic Marker of Pulmonary Vascular Disease. Chest. 2016;149(2):353-61.
  8. Lau EM, Godinas L, Sitbon O, Montani D, Savale L, Jais X, Lador F, Gunther S, Celermajer DS, Simonneau G, Humbert M, Chemla D, Herve P. Resting pulmonary artery pressure of 21-24 mmHg predicts abnormal exercise haemodynamics. Eur Respir J. 2016.
  9. Offen S, Jackson D, Canniffe C, Choudhary P, Celermajer DS. Dextrocardia in Adults with Congenital Heart Disease. Heart Lung Circ. 2016;25(4):352-7.
  10. Poh CL, Cochrane A, Galati JC, Bullock A, Celermajer DS, Gentles T, du Plessis K, Winlaw DS, Hornung T, Finucane K, d'Udekem Y. Ten-year outcomes of Fontan conversion in Australia and New Zealand demonstrate the superiority of a strategy of early conversiondagger. Eur J Cardiothorac Surg. 2016;49(2):530-5.
  11. Seneviratne MG, Grieve SM, Figtree GA, Garsia R, Celermajer DS, Adelstein S, Puranik R. Prevalence, distribution and clinical correlates of myocardial fibrosis in systemic lupus erythematosus: a cardiac magnetic resonance study. Lupus. 2016;25(6):573-81.
  12. Wilson TG, Iyengar AJ, Winlaw DS, Weintraub RG, Wheaton GR, Gentles TL, Ayer J, Grigg LE, Justo RN, Radford DJ, Bullock A, Celermajer DS, Dalziel K, Schilling C, d'Udekem Y. Use of ACE inhibitors in Fontan: Rational or irrational? Int J Cardiol. 2016;210:95-9.
  13. Choudhary P, Nandakumar R, Greig H, Broadhurst P, Dean J, Puranik R, Celermajer DS, Hillis GS. Structural and electrical cardiac abnormalities are prevalent in asymptomatic adults with myotonic dystrophy. Heart. 2016:1-7.
  14. Kapadia R, Choudhary P, Collins N, Celermajer D, Puranik R. Left Ventricular Non-compaction in Holt-Oram Syndrome. Heart Lung Circ. 2016;25(6):626-30.
  15. Iyengar AJ, Celermajer DS, Winlaw DS, D'Udekem Y. Young and Free: Over 25 Years of Seminal Contributions to Complex Congenital Heart Disease From Australia & New Zealand. Heart Lung Circ. 2016;25(6):529-34.
  16. Robertson S, Martinez GJ, Payet CA, Barraclough JY, Celermajer DS, Bursill C, Patel S. Colchicine Therapy in Acute Coronary Syndrome Patients acts on Caspase-1 to Suppress NLRP3 Inflammasome Monocyte Activation. Clin Sci (Lond). 2016.
  17. Tan JT, Prosser HC, Dunn LL, Vanags LZ, Ridiandries A, Tsatralis T, Leece L, Clayton ZE, Yuen SC, Robertson S, Lam YT, Celermajer DS, Ng MK, Bursill CA. High-Density Lipoproteins Rescue Diabetes-Impaired Angiogenesis via Scavenger Receptor Class B Type I. Diabetes. 2016;65(10):3091-103.
  18. Skilton MR, Nakhla S, Ayer JG, Harmer JA, Toelle BG, Leeder SR, Jones G, Marks GB, Celermajer DS. Telomere length in early childhood: Early life risk factors and association with carotid intima-media thickness in later childhood. Eur J Prev Cardiol. 2016;23(10):1086-92.
  19. Kapellas K, Mejia G, Bartold PM, Skilton MR, Maple-Brown LJ, Slade GD, O'Dea K, Brown A, Celermajer DS, Jamieson LM. Periodontal therapy and glycaemic control among individuals with type 2 diabetes: reflections from the PerioCardio study. Int J Dent Hyg. 2016.
  20. Iyengar AJ, Winlaw DS, Galati JC, Wheaton GR, Gentles TL, Grigg LE, Justo RN, Radford DJ, Attard C, Weintraub RG, Bullock A, Sholler GS, Celermajer DS, d'Udekem Y. No difference between aspirin and warfarin after extracardiac Fontan in a propensity score analysis of 475 patients. Eur J Cardiothorac Surg. 2016.
  21. Iyengar AJ, Celermajer DS, Winlaw DS, D'Udekem Y. Young and Free: Over 25 Years of Seminal Contributions to Complex Congenital Heart Disease From Australia & New Zealand. Heart Lung Circ. 2016;25(6):529-34.
  22. Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B, Narayanan K, Celermajer DS, Sidi D, Jouven X, Marijon E. Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. Circulation. 2016;133(24):2503-15.
  23. Cordina R, von Klemperer K, Kempny A, West C, Senior R, Celermajer DS, Gatzoulis MA, Babu-Narayan SV, Li W. Echocardiographic Predictors of Mortality in Adults With a Fontan Circulation. JACC Cardiovasc Imaging. 2016.
  24. Choudhary P, Nandakumar R, Greig H, Broadhurst P, Dean J, Puranik R, Celermajer DS, Hillis GS. Structural and electrical cardiac abnormalities are prevalent in asymptomatic adults with myotonic dystrophy. Heart. 2016;102(18):1472-8.
  25. Callaghan FM, Arnott C, Figtree GA, Kutty S, Celermajer DS, Grieve SM. Quantifying right atrial filling and emptying: A 4D-flow MRI study. J Magn Reson Imaging. 2016.
  26. Calderone A, Stevens W, Prior D, Nandurkar H, Gabbay E, Proudman SM, Williams T, Celermajer D, Sahhar J, Wong P, Thakkar V, Dwyer N, Wrobel J, Chin W, Liew D, Staples M, Buchbinder R, Nikpour M. M A multi-centre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol. BMJ Open. 2016
  27. Amarasena N, Kapellas K, Skilton MR, Maple-Brown LJ, Brown A, Bartold M, O'Dea K, Celermajer D, Jamieson LM. Factors Associated with Routine Dental Attendance among Aboriginal Australians. J Health Care Poor Underserved. 2016;27(1a):67-80.
  28. Bougouin W, Marijon E, Planquette B, Karam N, Dumas F, Celermajer DS, Jost D, Lamhaut L, Beganton F, Cariou A, Meyer G, Jouven X. Factors Associated With Pulmonary Embolism-Related Sudden Cardiac Arrest. Circulation. 2016;134(25):2125-7.
  29. Carins TA, Shi WY, Iyengar AJ, Nisbet A, Forsdick V, Zannino D, Gentles T, Radford DJ, Justo R, Celermajer DS, Bullock A, Winlaw D, Wheaton G, Grigg L, d'Udekem Y. Long-term outcomes after first-onset arrhythmia in Fontan physiology. J Thorac Cardiovasc Surg. 2016; 152(5):1355-63.e1.
  30. Clift P, Celermajer D. Managing adult Fontan patients: where do we stand? Eur Respir Rev. 2016; 25(142):438-50.
  31. Raghuveer G, White DA, Hayman LL, Woo JG, Villafane J, Celermajer D, Ward KD, de Ferranti SD, Zachariah J. Cardiovascular Consequences of Childhood Secondhand Tobacco Smoke Exposure: Prevailing Evidence, Burden, and Racial and Socioeconomic Disparities: A Scientific Statement From the American Heart Association. Circulation. 2016; 134(16):e336-e59.

Clinical Associate Professor Sanjay Patel

  1. Arnott C, Punia-Moorthy G, Tan J, Sadeghipour S, Bursill C, Patel S. The Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-associated Inflammatory Mediators on Vascular Endothelial Cells. PLOS One. 2016.
  2. Robertson, S, Martinez, G, Payet, C, Barraclough, J, Celermajer, D, Bursill C, Patel S.Colchicine Therapy in Patients Presenting with an Acute Coronary Syndrome acts on Caspase-1 to Suppress NLRP3 Inflammasome Monocyte Activation.  Clinical Science. 2016.

Dr Belinda Gray

  1. Gray B, Bagnall RD, Lam L, Ingles J, Turner C, Haan E, Davis A, Yang PC, Clancy CE, Sy RW, Semsarian C. A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2016;13(8):1652-60
  2. Burns C, Ingles J, Davis A, Connell V, Gray B, Hunt L, McGaughran J, Semsarian C. Clinical and genetic features of Australian families with long QT syndrome: a registry based study. J Arrhythm 2016; 13(8):456-461 
  3. Gray B, Behr ER. New Insights into the Genetic Basis of Inherited Arrhythmia Syndromes. Circ Cardiovasc Genet 2016;9(6): 569-577

Dr Kaivan Vaidya

  1. Vaidya K, Semsarian C, Chan KH. Atrial Fibrillation in Hypertrophic Cardiomyopathy. Heart Lung Circ. 2017 Sep;26(9):975-982. doi:10.1016/j.hlc.2017.05.116. Epub 2017 May 23. Review. PubMed PMID: 28602671.

Dr Kim Chan

  1. Chan KH, McGrady M, Wilcox I. A leadless intracardiac transcatheter pacing system. New England Journal of Medicine 2016;374:2604.
  2. Chan KH, Sy RW. Catheter ablation of recurrent ventricular fibrillation: a literature review and case examples. Heart, Lung and Circulation 2016;25:784-90.
  3. Chan KH, Santucci PA. Routine implant of biventricular devices guided by an electroanatomic mapping system - ready for prime-time? Journal of Atrial Fibrillation 2016;8:105-8.

Dr Rachel Cordina

  1. Cordina R,.. Li W. Echocardiographic predictors of mortality in adults with Fontan Circulation. JACC: Cardiovascular Imaging 2016; 10(2):221.
  2. Congenital Heart Disease Requires a Lifetime Continuum of Care: A call for a Regional Registry. Celermajer D, Cordina R,..d'Udekem Y. Heart, Lung and Circulation, 2016;25(8):750. 

Dr Lisa Simmons

  1. Moore BM, Ng HKB, Naoum C, Simmons L, Cartwright BL, Wilson MK, Ng MKC. Transcatheter Mitral Valve Replacement With a Novel Dual Stent Bioprosthesis. Circ Cardiovasc Interv. 2017 Jun;10(6). pii: e004841.
  2. Simmons, L. A. (2015), Utilisation of echocardiography in Australia. 
    Int Med J. 2015 45:1097-1099. (Invited editorial)


Professor Anthony Keech

  1. Brazionis L, A. J, Keech A, C. R, Bursell SE. Health-worker led retinal imaging, diabetes-related eye health education and lifestyle survey administration as a model for diabetic retinopathy screening in indigenous Australians with diabetes. ADS-ADEA Annual Scientific Meeting; 24-26 Aug 2016; Gold Coast.
  2. King E, Yuan J, Kong S, Dunn L, Stocker R, Keech A, Jenkins A, Ng M. Hypoxia tolerance in diabetes mellitus: the role of fenofibrate in facilitating protective metabolic reprogramming. 64th Cardiac Society of Australia and New Zealand Annual Scientific Meeting; 4-7 Aug 2016; Adelaide.
  3. Waldman B, Ansquer JC, Sullivan D, Jenkins A, McGill N, Buizen L, Feher M, Foucher C, Kesaniemi A, Flack J, D'Emden M, Hedley J, Keech A. Fenofibrate reduces uric acid levels and gout events in type 2 diabetes: results from the FIELD study. ADS-ADEA Annual Scientific Meeting; 24-26 Aug 2016; Gold Coast.
  4. Wong W, Joglekar MV, Januszewski AS, Farr RJ, Liuwantara D, Satoor S, Sahu S, Stanley E, Elefanty A, Kay T, Loudovaris T, Thomas H, O'Connell PJ, Lim E, Guillemin G, Martin D, Hawthorne WJ, Keech A, Jenkins A, Hardikar A. MicroRNAs of human insulin producing cells in pancreas, gallbladder and brain. ADS-ADEA Annual Scientific Meeting; 24-26 Aug 2016; Gold Coast.

Professor Anushka Patel

  1. Global Trends in Healthcare Delivery (plenary). South West Sydney Local Health District Annual Leaders Forum, Sydney (November 2016).
  2. Implementing and evaluating strategies for improved cardiovascular risk management in primary care. University of Notre Dame School of Medicine Research Conference 2016, Sydney (February 2016).
  3. Panel on Global Health Trends. BUPA ANZ Senior Managers Annual Meeting, Melbourne (February 2016). Travel and accommodation paid.

Professor Chris Semsarian

  1. Semsarian C, 2016. Hypertrophic cardiomyopathy: what's new in 2016. Heart Rhythm Society Scientific Meeting, San Francisco, USA.
  2. Semsarian C, 2016. Genetic testing to guide therapy: are we there yet? Heart Rhythm Society Scientific Meeting, San Francisco, USA.
  3. Semsarian C, 2016. Can we predict AF in HCM patients? HCM Summit, Toronto, Canada.
  4. Semsarian C, 2016. Sudden death in inherited cardiovascular disease and epilepsy. CARDIA Meeting, Stanford University, Napa Valley, USA.
  5. Semsarian C, 2016. Getting to the heart of sudden death. Cardiovascular Forum, Sheraton on the Park, Sydney.
  6. Semsarian C, 2016. Cardiac genomics and the potential for overdiagnosis. International Prevention of Overdiagnosis Conference, Barcelona, Spain.
  7. Semsarian C, 2016. The Colin Johnston Invited Lecture. Getting to the heart of sudden cardiac death. 2016 Joint Annual Scientific Meeting of AAS, HBPRCA, and AVBS, Hobart, Tasmania.
  8. Semsarian C, 2016. Hypertrophic cardiomyopathy: challenging the guidelines. American Heart Association Scientific Sessions, New Orleans, USA.
  9. Semsarian C, 2016. Genetics of hypertrophic cardiomyopathy and sudden death in the young. School of Biomedical Sciences, University of Queensland.
  10. Semsarian C, 2016. Cardiac genomics in Australia. Australian Genomics Health Alliance Workshop, Murdoch Children's Research Institute, Melbourne, Victoria.
  11. Semsarian C, 2016. Why do young people die suddenly? Sydney Local Health District Research and Innovation Symposium, Australian Technology Park, Sydney.
  12. Semsarian C, 2016. What's important in device therapy? ARVC Conference, Zurich, Switzerland.
  13. Semsarian C, 2016. The role of genetics in precision medicine. 64th CSANZ Scientific Meeting, Adelaide, South Australia.
  14. Semsarian C, 2016. Risk of sudden cardiac death, sports and ICD. 64th CSANZ Scientific Meeting, Adelaide, South Australia.
  15. Semsarian C, 2016. Results from a large ANZ population-based study. 64th CSANZ Scientific Meeting, Adelaide, South Australia.
  16. Semsarian C, 2016. Genetic testing in cardiomyopathy. 64th CSANZ Scientific Meeting, Adelaide, South Australia.
  17. Semsarian C, 2016. Risk stratification in hypertrophic cardiomyopathy. 9th Asia Pacific Heart Rhythm Society Scientific Meeting, Seoul, South Korea.
  18. Semsarian C, 2016. Arrhythmia genes in sudden death in epilepsy. 9th Asia Pacific Heart Rhythm Society Scientific Meeting, Seoul, South Korea.
  19. Semsarian C, 2016. Role of the molecular autopsy in sudden cardiac death. 9th Asia Pacific Heart Rhythm Society Scientific Meeting, Seoul, South Korea.
  20. Semsarian C, 2016. Twitter for heart health. NSW Health Public Affairs Forum, Royal North Shore Hospital, Sydney.
  21. Semsarian C, 2016. What your mentor should be telling you to stay competitive? CV ECR Workshop, Centenary Institute, University of Sydney.
  22. Semsarian C, 2016. The inherited cardiomyopathies. International Clinical Cardiovascular Genetics Meeting, Brisbane, Queensland.
  23. Semsarian C, 2016. Cardiac genetics in Australia. International Clinical Cardiovascular Genetics Meeting, Brisbane, Queensland.
  24. Semsarian C, 2016. MRI and sudden death. 6th Annual CMRS Cardiac MRI Masterclass. RPAH, Sydney.
  25. Semsarian C, 2016. Sudden death in 2016: HCM, LQTS and genetics. FRACP exam course, Royal Prince Alfred Hospital, Sydney.
  26. Semsarian C, 2016. Sudden cardiac death in the young. Focus Group, Charles Perkins Centre, University of Sydney.
  27. Semsarian C, 2016. What makes your heart stop? Raising the Bar University of Sydney Event, Harpoon Harry Hotel, Sydney.
  28. Semsarian C, 2016. Sudden cardiac death in the young. Royal Children's Hospital, Melbourne, Victoria.
  29. Semsarian C, 2016. Sudden cardiac death and findings of the ANZSCD study. RCPA "Heart with Mary Sheppard" Meeting, RCPA, Sydney.
  30. Semsarian C, 2016. Sudden death in athletes. RCPA "Heart with Mary Sheppard" Meeting, RCPA, Sydney.
  31. Semsarian C, 2016. Cardiomyopathies: presentation, treatment, prognosis and progression. RCPA "Heart with Mary Sheppard" Meeting, RCPA, Sydney.
  32. Semsarian C, 2016. Genetics of heart disease. Masters of Genetic Counselling Course, Kolling Institute, RNSH, Sydney.
  33. Semsarian C, 2016. Cardiac genetics in clinical practice. University of Western Australia, Perth, Western Australia.
  34. Semsarian C, 2016. Insights about life in Medicine. Combined Medical Association Meeting, University of Sydney.
  35. Semsarian C, 2016. Genetic testing in inherited heart diseases: is it useful? RACP Congress 2016, Adelaide, South Australia.
  36. Semsarian C, 2016. Is too much testing and treatment making us sick? Sydney Ideas Forum, University of Sydney, Sydney.
  37. Semsarian C, 2016. Cardiac genetics in clinical practice. Australian Association of Clinical Geneticists Annual Meeting, Charles Perkins Centre, Sydney.
  38. Semsarian C, 2016. Genetic heart diseases. USyd Physiology Year 3 Lecture Series, University of Sydney.
  39. Semsarian C, 2016. After a sudden death: molecular autopsy and family evaluation. 65th Annual Scientific Sessions of the American College of Cardiology, Chicago, USA.
  40. Semsarian C, 2016. Role of mentoring in women. Gender Equity Meeting. Centenary Institute, Sydney.

Professor David Celermajer

  1. Tricuspid Valve Pathologies. Structural Heart Disease of Australia, Sydney, February 2016.
  2. Left Atrial Decompression, Structural Heart Disease of Australia, Melbourne, July 2016.
  3. Pregnancy in Congenital Heart Disease. Cardiac Society of ANZ, Adelaide, Ausgust 2016.

Dr Belinda Gray

  1. International Clinical Cardiovascular Genetics Conference (ICCG) 2016

Dr Kim Chan

  1. "Event monitors for intermittent arrhythmias: real world experience” M Lim, E Rubenach, L Alifano, M McGrady, I Wilcox, KH Chan. Poster presentation, Cardiac Society of Australia and New Zealand Annual Scientific Meeting 2016.

Research Grants

Advanced Health Research Translational Centres Grant – NHMRC Celermajer, DS. (CIA) Rapid Access Chest Pain Clinic Evaluation  $10,000 2016-2017
China Center for mHealth Innovation Patel A, MacMahon S, Zhang P Qualcomm Wireless Reach.   US$1,500,000  2015-2018
Fred Hollows Found. Bursell S, Jenkins AJ, Brown A, O’Neal D, Keech A et al TEAMSNET  $3,600,000 2011-2016
Give2Asia on the advice of the Pfizer Foundation. Patel A, Praveen D, MacMahon S SMARThealth EXTEND   US$1,000,000  2016-2018
HCF Research Foundation  Patel A, Turnbull F Scholarships and Fellowship in Health Services Research  $431,810 2014-2017
Heart Foundation Women and Heart Disease Grant  Chief investigators: Professor Elizabeth Sullivan, Dr Rachael Cordina and Dr Lisa Simmons Heart to Heart: Longitudinal mothers' and babies' study of cardiac disease and pregnancy in NSW   $150,000 2016
HeartKids Grants-in-Aid Cardina, R. (CIA) Characterisation of Neurocognitive Function in people with a Fontan circulation   $50,000 2016
JDRF Australia Jenkins A, Keech AC, Craig M, Hardikar A, Joglekar M, Donaghue K, Fulcher G, Januszewski A The FAME 1 Eye Study – Preventing Vision Loss in T1 Diabetes  $1,253,000 2016- 2019
JDRF Australia Davis E, Jones T, Fournier P, Davey R, Shetty V, Smart C, Cross D, Geelhoed E, Grey M, Tamborlande W, Fegan G, Kaye J, Keech AC, King B Reducing hypoglycaemia and glycemic excursions caused by food and exercise in young people with T1D  $1,889,000 2016 – 2019
JDRF Australia O’Neal D, Jenkins A, Keech A, Colman P, Speight J, Ward G, Kumareswaran K, Holmes-Walker J, Evaluation of the Effiacy of Long Term Closed Loop Insulin Delivery in Improving Glycemic, Psychological and Cognitive outcomes in Adults with Type 1 Diabetes  $2,930,000 2016 - 2018
National Heart Foundation Vanguard Grant Semsarian, C. (CIA) Increasing physical activity in patients with hypertrophic cardiomyopathy: a pilot study  $75,000 2016
NHMRC Patel A Senior Research Fellowship [APP1079301]   $686,645 2015-2019
NHMRC  Chief Investigators: P Barter, DS Celermajer, Kritharides L, K-A Rye, W Jessup Atherosclerosis and Vascular Physiology Program Grant  $7,200,000 2013-2017
NHMRC 1024105 Keech AC Senior Principal Research Fellowship including SEO  $869,860 2013-2017
NHMRC 1037786 Simes RJ, Keech AC, Gebski V, Stockler M, Marschner I, Schofield D, CoIagiuri S, Caterson I. Improving Health Outcomes Through Clinical Research (Program Grant)  $10,600,000 2013-2017
NHMRC 1038739 Colagiuri S, Keech AC et al e-PREDICE EU-NHMRC Partnership Grant  $917,000 2013-2017
NHMRC 1066541 Ng M, Jrenkins AJ, Keech AC How fenofibrate protects from diabetic complications  $609,505 2014-2017
NHMRC 1067771 Brand-Miller J et al, Keech AC PREVIEW: Prevention of diabetes in Europe and around the World  $336,927 2014-2016
NHMRC 1069147 Jenkins AJ, Donaghue K, O’Neal D, Best JD, Keech AC (Study Chair) FAME (Fenofibrate and Microvascular Events) 1 Eye trial in T1D  $2,800,000 2014-2017
NHMRC 1070370 Tarnow-Mordie W et al, Keech AC (co-Chair) LEAP (Lactoferrin Evaluation in Anaemia of Pregnancy) 1 trial  $2,640,000 2014-2018
NHMRC 1078142 Skiltin M, KeechAC Reducing cardiovascular risk in children born with poor fetal growth. The small baby Omega-3     (SO3) trial  $951,296 2015 - 2019
NHMRC 1079864 Keech AC, Jenkins AJ, Henderson T, Brown A et al CRE in Diabetic Retinopathy  $2,490,000 2014-2019
NHMRC 1089056 Oie, JL, Tarnow-Mordi W, Lui K, Finer N, Saugstad O, Vento M, Buonocore G, Marlow N, Keech A TORPIDO2 Targeted Oxygen for Resuscitation of pre-term infants effects on developmental outcomes 2  $2,200,000 2015 - 2019
NHMRC 1104231 Simmons D, Hague W, Teede H, Cheung NW, Nolen C, Peek M, Girosi F, Cowell C, Keech AC The treatment of BOoking Gestational diabetes Mellitus study: The TOBOGM study  $2,200,000 2016 -2018
NHMRC 1105322 Simmer K, Strunk T, Tarnow-Mordi W, Patole S, Anderson A, Hague W, Doherty, Inder T, Marlow N, Barrington K, D, Keech AC Can Pentoxifylline improve long-term outcomes in preterm infants with late-onset sepsis or necrotizing enterocolitis  $2,900,000 2016 - 2020
NHMRC 1113592 Keech AC, Jenkins A, Sullivan D, Hardikar A, Ma R, Weiping Jia, Wang, Yu, Li Hauting. Biomarkers for risk Outcomes of Type 2 Diabetes.  $600,000 2016 -2020
NHMRC Centres of Research Excellence Semsarian, C. (CIF) ID# 1104136: Creating sustainable healthcare: ensuring new diagnostics avoid harms, improve outcomes, and direct resources wisely  $2,497,658 2016-2020
NHMRC Global Alliance Against Chronic Disease Grant  CIs: Patel A, Rodgers A, Prabhakaran D, Jan S, Webster R, Maulik P, Thom S [APP1040152] – Randomised controlled trial of early use of a simplified treatment regimen incorporating a half-dose, three-in-one blood pressure lowering pill vs. usual care for improving hypertension control in India  $1,067,559 2012-2017
NHMRC Global Alliance for Chronic Disease grant  Patel A, Zoungas S, Teede H, De Silva A, Naheed A, Jan S, Lombard C [APPAPP1093171] A lifestyle intervention program for the prevention of type 2 diabetes mellitus among South Asian women with gestational diabetes mellitus   $1,256,499 2015-2020
NHMRC Global Alliance for Chronic Disease grant  Peiris D, Zhang P, Ji L, Patel A, Xu J, Liang Z, Liu Y, Tian M, Essue B [APP1094712] -   Systematic Medical Assessment, Referral and Treatment for Diabetes care in China using Lay Family Health Promoters - SMART Diabetes  $1,385,858 2015-2018
NHMRC Partnership Grant  Celermajer, DS. Survival in Fontan Patients  $2,500,000 2015-2019
NHMRC Program Grant  CIs: MacMahon S, Chalmers J, Neal B, Woodward M, Anderson C, Patel A, Rodgers A, Perkovic V [APP1052555] – Discovery and translation of evidence for new strategies to combat cardiovascular diseases   $17,802,750 2014-2018
NHMRC Project Grant Semsarian, C. (CIB) Grant ID# 1103782: A novel therapy for the prevention and treatment of familial hypertrophic cardiomyopathy   $835,972 2016-2019
NHMRC Project Grant Semsarian, C. (CIA) Grant ID# 11098931: Genetic basis of childhood cardiomyopathy  $1,012,046 2016-2020
NHMRC Project Grant Patel A, Peiris D, Saini B, Joshi R, Usherwood T, Armour C, Webster R, Lo S [APP1084657] – An integrated general practice and pharmacy-based intervention to promote the prescription and use of appropriate preventive medications among individuals at high cardiovascular risk   $2,296,358 2015-2018
NIH (NIMH) PIs: Wu Y, Yu X; Co-Is: Sikemma K, Blumenthal J, Patel A, Maulik P [1R01MH100332-01] – Integrating depression care for ACS patients in low resource hospitals in China   US$1,735,756  2014-2017
Novartis Educational Grant Patel, S. Novartis Educational Grant  $220,000 2015-
NSW Genomics Collaborative Grants Program Semsarian, C. (CIA) Clinical application of whole genome studies in patients with inherited cardiomyopathies   $320,000 2016-2017
Perpetual Foundation  Patel, S. Perpetual Foundation   $70,000 2016-
Qatar National Research Foundation Hardikar A, Keech AC, Jenkins A, Joglekar M, Januszewski A. 1000 QatarOmics Study: Epigenetics in T2D  $1,000,000 2016 - 2019
RT Hall Foundation Project Grant Semsarian, C. (CIA) Expansion of the indigenous inherited heart disease clinic   $180,000 2016-2018

Contact details for department

Head of Department: Dr Mark Adams

Department/Unit: Cardiology
RPA Hospital
Missenden Road
Camperdown NSW 2050
Web: www.slhd.nsw.gov.au/research/
Email: mark.adams@email.cs.nsw.gov.au